Valganciclovir
Epstein-Barr Virus-Associated Mesenchymal Tumor
Explore 4 assets in Epstein-Barr Virus-Associated Mesenchymal Tumor →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Viracta Therapeutics, Inc.
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05166577CT.gov Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Epstein-Barr Virus-Associated Mesenchymal Tumor
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Valganciclovir (this asset) | Viracta Therapeutics, Inc. | P1 | CC · 43 |
| Tabelecleucel | Pierre Fabre Medicament | P2 | CCC |
| Pembrolizumab | Viracta Therapeutics, Inc. | P1 | CC |
| Nanatinostat | Viracta Therapeutics, Inc. | P1 | C |
Other indications for Valganciclovir
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cytomegalovirus Infection | — | P3 | BB · 68 |
| Lymphoproliferative Syndrome | — | P2 | B · 61 |
| Epstein-Barr Virus-Associated Lymphoproliferative Disorder | — | P2 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Valganciclovir in Epstein-Barr Virus-Associated Mesenchymal Tumor. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/valganciclovir-epstein-barr-virus-associated-mesenchymal-tumor
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →